Immunomodulation and therapeutic characterization of thymosin fraction five

James E. Talmadge; Keith A. Uithoven; Barbara F. Lenz; Michael Chirigos

doi:10.1007/BF00205510

Immunomodulation and therapeutic characterization of thymosin fraction five

James E. Talmadge, Keith A. Uithoven, Barbara F. Lenz, Michael Chirigos

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.

Original language	English (US)
Pages (from-to)	185-194
Number of pages	10
Journal	Cancer Immunology Immunotherapy
Volume	18
Issue number	3
DOIs	https://doi.org/10.1007/BF00205510
State	Published - Dec 1984
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology
Cancer Research

Access to Document

10.1007/BF00205510

Cite this

@article{23d37415818a4bf9b2a342a809282dce,

title = "Immunomodulation and therapeutic characterization of thymosin fraction five",

abstract = "In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.",

author = "Talmadge, {James E.} and Uithoven, {Keith A.} and Lenz, {Barbara F.} and Michael Chirigos",

year = "1984",

month = dec,

doi = "10.1007/BF00205510",

language = "English (US)",

volume = "18",

pages = "185--194",

journal = "Cancer Immunology Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Immunomodulation and therapeutic characterization of thymosin fraction five

AU - Talmadge, James E.

AU - Uithoven, Keith A.

AU - Lenz, Barbara F.

AU - Chirigos, Michael

PY - 1984/12

Y1 - 1984/12

N2 - In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.

AB - In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.

UR - http://www.scopus.com/inward/record.url?scp=0021681966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021681966&partnerID=8YFLogxK

U2 - 10.1007/BF00205510

DO - 10.1007/BF00205510

M3 - Article

C2 - 6239686

AN - SCOPUS:0021681966

SN - 0340-7004

VL - 18

SP - 185

EP - 194

JO - Cancer Immunology Immunotherapy

JF - Cancer Immunology Immunotherapy

IS - 3

ER -

Immunomodulation and therapeutic characterization of thymosin fraction five

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this